Bli medlem
Bli medlem

Du är här

2016-11-15

MorphoSys AG: MorphoSys to Raise Capital via a Private Placement of New Shares

MorphoSys AG / MorphoSys to Raise Capital via a Private Placement of New
Shares. Processed and transmitted by Nasdaq Corporate Solutions. The issuer
is solely responsible for the content of this announcement.
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX;
OTC: MPSYY) today announced the launch of a private placement of up to
2,622,088 new shares to institutional investors in Europe and North America
via an accelerated book building transaction.

"MorphoSys has successfully broadened its development pipeline that currently
stands at a record high of 110 programs, 28 of which are in clinical
development," said Jens Holstein, Chief Financial Officer of MorphoSys AG.
"With the proceeds of this offering, we plan to further support our
transition into a late-stage biotech company based on our advancing
proprietary pipeline with a clear focus on oncology and selected highly
promising programs in inflammation."

MorphoSys will offer up to 2,622,088 new shares from authorized capital, or up
to approximately 9.9% of the registered share capital, to qualified and other
eligible investors. The new shares will be issued excluding pre-emptive
rights and are scheduled to be admitted to listing on the Frankfurt Stock
Exchange following their issuance. Book building will commence immediately.
It is anticipated that books will close tomorrow, although the bookrunners
reserve the right to close the books at any time. In connection with the
placement, BVF Partners, L.P. and affiliates, a San Francisco-based
specialist biotech investor intends to place an order for approx. 1.2 million
shares. MorphoSys will be subject to a customary lock-up of 90 days.

MorphoSys plans to use the net proceeds from the transaction in particular to:

* Fund the further clinical development of MOR208, the Company's wholly owned
investigational anti-CD19 antibody, which is currently in two phase 2
combination studies in diffuse large B-cell lymphoma (DLBCL), one of which
is expected to be transitioned into a pivotal phase 3 study next year. In
addition, it is intended to start an additional phase 2 combination study
with MOR208 in chronic lymphocytic leukemia (CLL);
* Fund the further clinical development of MorphoSys's wholly owned program
MOR202, an anti-CD38 antibody currently in a phase 1/2a clinical trial in
multiple myeloma;
* Advance MorphoSys's co-development programs MOR106, an anti-IL-17C antibody
jointly developed together with Galapagos currently in a phase 1 clinical
trial in atopic dermatitis, as well as MOR209, a bi-specific antibody
targeting PSMA and CD3, jointly developed together with Aptevo Therapeutics
(formerly Emergent BioSolutions) in castration-resistant prostate cancer;
* Start clinical development of MOR107, a constrained peptide with potential
in fibrotic diseases developed by Lanthio Pharma, a wholly owned subsidiary
of MorphoSys;
* Initiate, advance and/or accelerate the development of other proprietary
programs, including advancing of pre-clinical or clinical stage assets into
later stages of clinical development prior to licensing;
* Fund potential in-licensing of oncology product candidates and/or
acquisition/in-licensing of additional technologies.

Deutsche Bank and J.P. Morgan will act as Joint Bookrunners for the offering.

Disclaimer:
This press release is for information only and does not constitute an offer to
sell, purchase, exchange or transfer any securities or a solicitation of any
such offer in the United States or any other jurisdiction. The securities
referred to herein have not been and will not be registered under the U.S.
Securities Act of 1933, as amended (the "Securities Act") and may not be
offered or sold in the United States absent registration or an exemption from
registration under the Securities Act. Neither MorphoSys AG (the "Seller")
nor any other participant in the transaction described herein intends to
register any securities under the Securities Act or with any securities
regulatory authority of any state or other jurisdiction in the United States
in connection with the proposals described in this announcement.

Deutsche Bank AG and J.P. Morgan Securities plc are acting solely for the
Seller and no one else and will not be responsible for providing the
protections afforded to customers of Deutsche Bank AG and J.P. Morgan
Securities plc nor for providing advice in relation to the transaction.

The shares may not be offered to the public in any jurisdiction in
circumstances which would require the preparation or registration of any
prospectus or offering document relating to the shares in such jurisdiction.

No action has been taken by the Seller or Deutsche Bank AG and J.P. Morgan
Securities plc or any of their respective affiliates that would permit an
offering of the shares or possession or distribution of this announcement or
any other offering or publicity material relating to such securities in any
jurisdiction where action for that purpose is required.

In member states of the European Economic Area ("EEA"), this announcement and
any offer if made subsequently is directed only at persons who are "qualified
investors" within the meaning of Article 2(1)(e) of the Prospectus Directive
(Directive 2003/71/EC) ("Qualified Investors"). Any person in the EEA who
acquires the securities in any offer (an "investor") or to whom any offer of
the securities is made will be deemed to have represented and agreed that it
is a Qualified Investor. Any investor will also be deemed to have represented
and agreed that any securities acquired by it in the offer have not been
acquired on behalf of persons in the EEA other than Qualified Investors or
persons in the UK and other member states (where equivalent legislation
exists) for whom the investor has authority to make decisions on a wholly
discretionary basis, nor have the securities been acquired with a view to
their offer or resale in the EEA to persons where this would result in a
requirement for publication by the Seller or Deutsche Bank AG and J.P. Morgan
Securities plc of a prospectus pursuant to Article 3 of the Prospectus
Directive. The Seller and Deutsche Bank AG and J.P. Morgan Securities plc and
any of their affiliates, and others will rely upon the truth and accuracy of
the foregoing representations and agreements.

In the United Kingdom, this document is only being distributed to and is only
directed at persons who (i) are investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred
to as "Relevant Persons"). This document is directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant
Persons. Any investment or investment activity to which this document relates
is available only to Relevant Persons and will be engaged in only with
Relevant Persons.

About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 100 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications&IR

Jochen Orlowski
Associate Director Corporate Communications&IR

Alexandra Goller
Senior Manager Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media Release (PDF)
http://hugin.info/130295/R/2057159/770677.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.